Congenital enteropathy due to enteropeptidase deficiency is a rare genetic condition that affects digestion from birth or early infancy. Babies with this condition often have poor weight gain, chronic diarrhea, and greasy stools, and doctors may see signs of malnutrition. It is lifelong, but early diagnosis and careful nutrition support can improve growth and energy. Treatment focuses on pancreatic enzyme replacement, special formulas or high-calorie diets, and vitamin and mineral supplementation. Not everyone will have the same experience, and with close care many children with congenital enteropathy due to enteropeptidase deficiency can do well.
Overview
Congenital enteropathy due to enteropeptidase deficiencySymptoms
Congenital enteropathy due to enteropeptidase deficiency in infants causes chronic diarrhea, bulky greasy stools, vomiting, and poor weight gain after feeds. Features include a distended belly, swelling from low protein, and muscle weakness, typically appearing soon after birth.
Outlook and prognosis
Many living with congenital enteropathy due to enteropeptidase deficiency improve with early diagnosis, enzyme replacement, and careful nutrition. Growth often catches up, and hospitalizations become less frequent. Ongoing follow-up helps manage feeding, vitamin support, and intermittent flare‑ups.
Causes and risk factors
Congenital enteropathy due to enteropeptidase deficiency stems from autosomal recessive TMPRSS15 gene changes. Risk is higher when both parents are carriers, especially with parental relatedness; environment doesn’t cause it but infections or poor nutrition can worsen severity.
Genetic influences
Genetics are central in congenital enteropathy due to enteropeptidase deficiency. Most cases result from inherited mutations in the TMPRSS15 gene, usually autosomal recessive. Family history, consanguinity, or affected siblings increase risk; carrier testing and prenatal options exist.
Diagnosis
Doctors suspect it in infants with severe diarrhea, poor weight gain, and low blood proteins. Diagnosis of congenital enteropathy due to enteropeptidase deficiency is confirmed by absent enteropeptidase activity on duodenal biopsy and genetic tests of TMPRSS15.
Treatment and drugs
Treatment focuses on replacing missing nutrients, supporting growth, and easing diarrhea in congenital enteropathy due to enteropeptidase deficiency. Doctors often use specialized formulas, pancreatic enzyme therapy, fat‑soluble vitamins, and careful feeding plans. Some children also benefit from temporary tube feeding or IV nutrition.
Symptoms
Parents often notice feeding difficulties, loose or greasy stools, and slow weight gain in the first months of life. Early on, this might look like trouble gaining weight, frequent bulky stools, and swelling of the legs or face. The early features of congenital enteropathy due to enteropeptidase deficiency come from the body struggling to break down protein, so nutrients aren’t absorbed well. Signs often become more noticeable soon after milk or solid foods are introduced.
In congenital enteropathy due to enteropeptidase deficiency, babies may not gain weight as expected or may even lose weight. Clothes seem to fit the same week to week, and growth chart lines can start to flatten.
Stools are loose or watery several times a day. This can lead to diaper rash and make it harder to stay hydrated.
With enteropeptidase deficiency, bowel movements can look pale, bulky, or oily and have a very strong smell. They may leave an oily ring in the diaper or be hard to flush.
Puffiness around the eyes, face, or ankles can appear when blood protein is low. You may also notice a rounder belly from fluid buildup (edema).
How people usually first notice Congenital enteropathy due to enteropeptidase deficiency?
Many families first notice signs within days after birth when a full‑term newborn has trouble feeding, persistent vomiting, poor weight gain, and stools that look bulky, pale, or greasy from undigested fat. Doctors may suspect congenital enteropathy due to enteropeptidase deficiency during early check-ups when a baby shows failure to thrive, low muscle tone, or swelling from low protein levels, and blood tests reveal very low trypsin activity despite a normal pancreas. In practice, the first signs of congenital enteropathy due to enteropeptidase deficiency are often recognized in infancy as severe fat and protein malabsorption that doesn’t improve with usual feeding adjustments.
Types of Congenital enteropathy due to enteropeptidase deficiency
Congenital enteropathy due to enteropeptidase deficiency is a rare, inherited condition that affects how the small intestine activates digestive enzymes, especially those needed to break down proteins. Types of congenital enteropeptidase deficiency are generally based on how much enzyme activity remains and whether the deficiency is present from birth or acquired later. Clinicians often describe them in these categories: complete deficiency and partial (residual) deficiency, with a rare acquired form reported after severe intestinal injury. Not everyone will experience every type, and early symptoms of congenital enteropeptidase deficiency can look different across these forms.
Complete deficiency
Symptoms begin in the first weeks of life with poor weight gain and large, greasy stools. Babies may have swelling from low protein levels and frequent vomiting. Without enzyme replacement via diet changes and support, growth can stall.
Partial deficiency
Symptoms may appear later and be milder, such as slower growth, belly bloating, and loose stools after high‑protein meals. Some people tolerate small protein amounts but struggle with larger portions. The balance of symptoms can shift over time.
Acquired deficiency
A rare, non‑genetic form can follow severe small‑intestinal injury or surgery. People may notice new digestive issues and protein malabsorption after the triggering event. Recovery depends on healing of the intestine and nutrition support.
What genetics can tell you about symptoms
People with enteropeptidase deficiency often have poor weight gain, chronic diarrhea, and swollen belly in infancy because they can’t activate digestive enzymes to break down protein. Variants in the TMPRSS15 gene disrupt enteropeptidase, leading to protein malabsorption and nutrient deficiencies.
Causes and risk factors
The root cause is a change in the TMPRSS15 gene that stops the gut enzyme enteropeptidase from working. It is usually inherited in an autosomal recessive way, meaning both parents carry a silent gene change. Family history and parents related by blood raise the chance, while undernutrition and infections can make the illness more severe. Because the enzyme is missing from birth, early symptoms of Congenital enteropathy due to enteropeptidase deficiency often appear in infancy. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Congenital enteropathy due to enteropeptidase deficiency begins before birth and, for most families, does not seem tied to events during pregnancy or delivery. Doctors often group risks into internal (biological) and external (environmental). So far, research has not identified clear environmental or body-based triggers for this condition. The points below summarize environmental and biological risk factors for congenital enteropathy due to enteropeptidase deficiency that have been studied.
Advanced maternal or paternal age is linked to some birth conditions, but there is no consistent evidence it increases the likelihood of congenital enteropathy due to enteropeptidase deficiency. Most reported cases have not shown a clear age pattern.
Conditions such as diabetes or thyroid disease can affect overall pregnancy outcomes, yet they have not been shown to cause this specific deficiency. Routine prenatal care remains important for general fetal health.
High-dose radiation, heavy metals, and certain chemicals can raise the risk of some birth differences, but no link has been shown with congenital enteropathy due to enteropeptidase deficiency. Avoiding toxic exposures remains good practice in pregnancy, even though a direct connection to this condition has not been demonstrated.
Some infections during pregnancy can affect fetal development, yet they have not been associated with a higher risk of this deficiency. Preventing and treating infections supports overall pregnancy health.
Genetic risk factors
Congenital enteropathy due to enteropeptidase deficiency stems from changes in the TMPRSS15 gene that leave the enzyme underactive or missing. Carrying a genetic change doesn’t guarantee the condition will appear. The genetic causes of congenital enteropeptidase deficiency follow an autosomal recessive pattern, where a child must inherit two nonworking copies to be affected. Family risk depends on who in the family carries a TMPRSS15 change.
TMPRSS15 variants: Pathogenic changes in the TMPRSS15 gene prevent the small intestine from making enough enteropeptidase. Without this enzyme, trypsinogen isn’t activated properly, which interrupts protein digestion. Loss-of-function variants such as missense, nonsense, splice, or deletions are the usual cause.
Autosomal recessive: The condition occurs when a child inherits two nonworking TMPRSS15 copies—one from each parent. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of an affected child. Each child also has a 50% (1 in 2) chance to be a healthy carrier.
Carrier status: People with one TMPRSS15 change usually have no symptoms but can pass the change to their children. Identifying carriers through family-based or targeted genetic testing can clarify who is at risk for having an affected child.
Family history: Having an affected sibling or known TMPRSS15 variants in close relatives increases the chance another child could be affected. Once a familial variant is found, relatives can be offered targeted testing to understand their personal risk.
Consanguinity risk: Parents who are related by blood or come from the same small ancestry group are more likely to carry the same TMPRSS15 variant. This increases the likelihood their children inherit two copies and develop the condition.
Variant severity: Different TMPRSS15 changes can reduce enzyme activity to different degrees, which may influence how early or severe symptoms appear. Still, risk is just one side of the picture, and severity can vary even among siblings with the same variants.
Lifestyle risk factors
Lifestyle habits do not cause this genetic condition, but they can meaningfully shape symptoms, growth, and complication risk. Diet composition and feeding routines often determine how much diarrhea, malabsorption, and failure to thrive occur. Hydration and micronutrient strategies also influence hospitalizations and development. The points below summarize how lifestyle affects Congenital enteropathy due to enteropeptidase deficiency and outline practical lifestyle risk factors for Congenital enteropathy due to enteropeptidase deficiency.
Intact whole-protein foods are harder to digest when trypsin activation is impaired and can worsen diarrhea and malnutrition. Using amino acid–based or extensively hydrolyzed protein sources usually reduces symptoms.
Standard cow’s milk or soy formulas with intact proteins often exacerbate malabsorption. Amino acid–based formulas are better tolerated and support growth in this condition.
Early introduction of meats, eggs, or dense protein solids can increase stool output and weight faltering. Delaying or modifying these foods until a tolerated protein form is established may prevent setbacks.
Large, infrequent meals can overwhelm limited proteolytic capacity and trigger diarrhea. Smaller, more frequent feeds may improve absorption and energy balance.
Risk prevention
Congenital enteropathy due to enteropeptidase deficiency can’t be prevented before birth, but you can lower the risk of complications and support healthy growth with early, tailored care. Prevention is about lowering risk, not eliminating it completely. Spotting early symptoms of congenital enteropathy due to enteropeptidase deficiency—such as persistent diarrhea and poor weight gain—helps families and clinicians act sooner. Planning nutrition, monitoring growth, and coordinating care make the biggest difference over time.
If this condition runs in your family, counseling can explain inheritance and your chances in future pregnancies. Carrier testing, prenatal testing, or IVF with embryo testing may be options for some families.
When a gene change is known in the family, testing siblings or future pregnancies can identify who is affected early. Early confirmation means feeding support and treatment can start before complications build up.
Watch for early symptoms of enteropathy—ongoing diarrhea, poor weight gain, or swelling from low protein—and seek medical evaluation. Early diagnosis of enteropeptidase deficiency allows quicker nutrition support and enzyme-based treatments when prescribed.
A dietitian can guide high-calorie feeds and hydrolyzed or elemental formulas that are easier to absorb. This helps prevent malnutrition and supports catch-up growth.
Transmission
Congenital enteropathy due to enteropeptidase deficiency is not contagious—you can’t catch it or pass it through everyday contact. If you’re wondering how congenital enteropathy due to enteropeptidase deficiency is inherited, it follows an autosomal recessive pattern: a child develops the condition when they receive two nonworking copies of the gene, one from each carrier parent who typically have no symptoms. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child with two working copies. Very rarely, genetic transmission of congenital enteropathy due to enteropeptidase deficiency can involve a new mutation in a child, but the condition still isn’t spread between people.
When to test your genes
Consider genetic testing if you or a child has lifelong poor weight gain, chronic diarrhea, and low trypsin activity suggesting protein digestion problems, especially in infancy. Testing is also reasonable with a family history or if you’re from a community with known cases. A confirmed diagnosis can guide enzyme replacement, nutrition plans, and family planning.
Diagnosis
In newborns and young infants, clues often appear soon after feeds begin—frequent watery stools, poor weight gain, and swelling from low protein levels. Finding out the cause is the first step toward treatment. For many, the diagnosis of Congenital enteropathy due to enteropeptidase deficiency is based on these early signs plus targeted tests. The genetic diagnosis of Congenital enteropathy due to enteropeptidase deficiency is confirmed by measuring enzyme activity and checking the gene involved.
Doctors ask when symptoms started, how feeding affects stools, and whether there is swelling or poor growth. A detailed family and health history can help identify patterns that suggest a rare inherited condition.
Providers compare weight, length/height, and head growth over time. Slowed or faltering growth supports an intestinal cause and helps judge urgency of testing.
Tests often look at protein levels (albumin), electrolytes, and vitamin status. Low protein and signs of dehydration can support an intestinal absorption problem.
Measuring fat in stool helps show if nutrients are being lost instead of absorbed. High fecal fat suggests malabsorption, which fits with this condition.
Stages of Congenital enteropathy due to enteropeptidase deficiency
Congenital enteropathy due to enteropeptidase deficiency does not have defined progression stages. It’s present from birth and tends to show up early with feeding difficulties and poor weight gain, but it doesn’t follow a step-by-step worsening pattern. Different tests may be suggested to help confirm the cause, such as blood and stool checks for nutrient loss, an upper endoscopy with small-intestine sampling, and genetic testing. Doctors usually recognize early symptoms of congenital enteropathy due to enteropeptidase deficiency in infancy and then monitor growth, nutrition, and response to treatment over time.
Outlook and prognosis
Living with congenital enteropathy due to enteropeptidase deficiency, many families wonder how growth, nutrition, and daily energy will look over time. Early care can make a real difference, especially when teams move quickly to support feeding, prevent dehydration, and correct nutrient gaps. In the first months and years, children with this condition may have trouble gaining weight and may tire easily; with targeted nutrition plans, enzyme replacement where available, and careful monitoring, many regain strength and begin to follow their own growth curve. Everyone’s journey looks a little different.
Looking at the long-term picture can be helpful. Prognosis refers to how a condition tends to change or stabilize over time. For congenital enteropathy due to enteropeptidase deficiency, the long-term outlook usually hinges on how quickly the diagnosis is made and how well nutrition is supported. Some children need temporary tube feeding or specialized formulas; others transition to regular eating with supplements and see steady catch-up growth through childhood.
Serious complications are most likely early on, when dehydration, low blood sugar, or severe malnutrition can occur if the condition is not recognized. With consistent care and follow-up, many people maintain good growth and avoid hospital stays, and overall survival is generally favorable in settings with access to pediatric gastroenterology and nutrition support. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Ask about early warning signs and what steps to take if they appear.
Long-term effects
Congenital enteropathy due to enteropeptidase deficiency often begins in infancy with poor weight gain and diarrhea, and its long-term effects reflect years of challenges with digestion and nutrition. Long-term effects vary widely, and they can change from childhood to adulthood. With diagnosis and ongoing medical care, many people grow, learn, and take part in everyday life, though some health issues may persist.
Early faltering in weight and length is common, with catch-up growth possible later. Adult height varies, and some remain shorter than peers. Patterns often stabilize after early childhood.
Ongoing risks include low protein and fat-soluble vitamin levels. This can lead to edema, anemia, easy bruising, vision problems in low light, or nerve and muscle issues. Monitoring often focuses on vitamins A, D, E, and K.
Low bone mineral density can develop over time from poor absorption. This may raise the chance of fractures and bone pain. Growth plates in children can be affected before stabilizing.
Loose, bulky, or greasy stools may persist or recur. Bloating and abdominal discomfort can wax and wane across the years. Some experience fewer flares as they get older.
How is it to live with Congenital enteropathy due to enteropeptidase deficiency?
Living with congenital enteropathy due to enteropeptidase deficiency often means navigating chronic diarrhea, poor weight gain, and fatigue in infancy and childhood, with careful attention to specialized nutrition and enzyme replacement where available. Daily life can revolve around frequent feeds, tracking growth, managing dehydration risks, and coordinating care with gastroenterology and nutrition teams, which can be tiring but becomes more predictable with a clear plan. For families, routines may shift around medical appointments and meal preparation, and siblings or caregivers may feel the strain, yet many find relief as symptoms improve with tailored diets, fat-soluble vitamin support, and monitoring. Over time, people can gain strength and catch up on growth, and with consistent care, school, play, and social life become increasingly manageable.
Treatment and drugs
Treatment for congenital enteropathy due to enteropeptidase deficiency focuses on replacing missing digestive activity, protecting nutrition, and supporting growth. Doctors often start with a special formula or diet that limits long protein chains and uses easily absorbed nutrients, plus vitamin and mineral supplements; some centers use pancreatic enzyme or peptide-based products to help digestion, though availability varies by region. If dehydration or poor weight gain occurs, short-term feeding through a tube or IV nutrition may be needed until the gut can safely handle more, and a dietitian usually helps fine-tune intake as children grow. Treatment plans often combine several approaches, and regular follow-up tracks weight, height, hydration, and lab markers to adjust therapy over time. Keep track of how you feel, and share this with your care team.
Non-drug treatment
Daily care focuses on nutrition, hydration, and growth so children can gain strength and thrive at home. Non-drug treatments often lay the foundation for medical care by meeting calorie and protein needs in ways the body can absorb. Plans are individualized and can change as your child grows and symptoms settle or flare. Teams usually include a pediatrician, gastroenterologist, and dietitian familiar with congenital enteropathy due to enteropeptidase deficiency.
Free amino acid–based formulas bypass the need to digest proteins. They can reduce diarrhea and support weight gain. A dietitian can help choose options available in your region.
Peptide-based formulas may work for some once symptoms are steadier. They are easier to absorb than whole-protein feeds. This can be a bridge toward a more typical diet.
Medium-chain triglycerides are absorbed more easily and can boost calories. They may help without worsening diarrhea. Your care team can guide safe amounts to add.
When absorption is too low or during severe illness, intravenous nutrition can meet needs. It supports growth and hydration while the gut recovers. Regular monitoring helps prevent line and liver complications.
Your genes may have an impact on how drugs work for you
Genes can affect how well certain nutrition supports, pancreatic enzyme replacements, and fat-soluble vitamin supplements work, and how your body handles related medicines. Pharmacogenetic testing may guide dosing or choice, helping tailor treatment and reduce side effects.
Pharmacological treatments
Treatment focuses on replacing the missing digestive activity, protecting the enzymes so they work where needed, and preventing nutrition gaps. Because early symptoms of congenital enteropathy due to enteropeptidase deficiency include poor weight gain and diarrhea, medicines aim to improve protein digestion and absorption. Not everyone responds to the same medication in the same way. Your care team will individualize doses and combinations based on growth, stool changes, and blood tests.
Pancrelipase capsules (such as Creon, Pancreaze, or Zenpep) supply active proteases to help break down dietary protein. The enteric coating delivers enzymes to the small intestine where they can work.
Proton pump inhibitors like omeprazole or esomeprazole, or H2 blockers such as famotidine, lower stomach acid to protect enzyme supplements. This can make pancrelipase more effective in the gut.
Vitamins A (retinol), D3 (cholecalciferol), E (alpha-tocopherol), and K (phytonadione) are supplemented to prevent or treat deficiencies. The form and dose are adjusted to lab results and age.
Iron (ferrous sulfate) and zinc are used if tests show low levels or signs of anemia or poor growth. Your clinician will monitor levels and change doses as needs evolve.
Genetic influences
This condition is usually inherited in a recessive way: a child is affected only if they receive two non-working copies of the gene that helps make the enteropeptidase enzyme. Parents typically each carry one changed copy and feel well; a “carrier” means you hold the gene change but may not show symptoms. The gene most often involved is called TMPRSS15, and certain changes in this gene reduce or block the body’s ability to switch on key digestive enzymes. Because enzyme activity can vary by the exact gene change, severity and timing of symptoms can differ, even among siblings. Genetic testing for congenital enteropathy due to enteropeptidase deficiency can look for changes in TMPRSS15 and help confirm the diagnosis alongside clinical findings. If both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child without the gene change.
Is Congenital enteropathy due to enteropeptidase deficiency genetic?
Genetics are central in congenital enteropathy due to enteropeptidase deficiency. Most cases result from inherited mutations in the TMPRSS15 gene, usually autosomal recessive. Family history, consanguinity, or affected siblings increase risk; carrier testing and prenatal options exist.
Pharmacogenetics—how genetics influence drug effects
In this condition, inherited changes in the enteropeptidase gene shape treatment choices more than they change the list of medicines used. Because the intestine lacks the switch that turns on protein-digesting enzymes, standard pancreatic enzyme capsules and high‑protein feeds may not be enough; many do better with amino acid–based or predigested formulas, and in some centers, carefully supervised trials of enzyme replacement are considered. Alongside medical history and nutrition needs, genetic testing for Congenital enteropathy due to enteropeptidase deficiency can help confirm the diagnosis and set realistic expectations for which therapies are likely to help. The exact genetic change can hint at whether any enzyme activity remains, which may explain why one child tolerates more intact protein while another needs elemental formulas. Response to feeds and supplements also depends on growth, gut inflammation, and overall health at the time. For most other medicines, Congenital enteropathy due to enteropeptidase deficiency doesn’t change dosing directly, though serious malabsorption can alter how well oral drugs are absorbed, so doctors may adjust formulations or use non‑oral routes if needed.
Interactions with other conditions
Living with congenital enteropathy due to enteropeptidase deficiency, other gut or pancreatic problems can magnify malabsorption and growth concerns. Doctors call it a “comorbidity” when two conditions occur together. For example, pancreatic enzyme insufficiency (as seen in cystic fibrosis or certain rare pancreatic disorders) can compound the lack of enzyme activation, leading to more severe diarrhea, poor weight gain, and vitamin shortages. Conditions that injure the small intestine—such as celiac disease or a lingering intestinal infection—may further reduce nutrient uptake and make early symptoms of congenital enteropathy due to enteropeptidase deficiency harder to tell apart from a flare of something else. Small intestinal bacterial overgrowth or a shortened bowel after surgery can also intensify bloating, gas, and fat in the stool. Because protein loss can weaken immunity and lower energy, common childhood viruses or gastroenteritis may hit harder, so coordinated care and nutrition support help break this cycle.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of infants who failed to gain weight despite plentiful feeding, with bulky, greasy stools and profound tiredness. In some places, elders recalled a baby who seemed well at birth but soon struggled after milk feeds were introduced, while a sibling had faced something similar years earlier. These stories captured the everyday impact of what we now recognize as congenital enteropathy due to enteropeptidase deficiency.
First described in the medical literature as a severe form of malabsorption in early infancy, the condition was initially pieced together from careful bedside observations. Doctors noted that standard causes of poor growth did not fit. Blood tests hinted at problems breaking down protein, and stools showed undigested fat. Yet the exact step that was blocked in digestion remained unclear for years.
From early theories to modern research, the story of congenital enteropathy due to enteropeptidase deficiency traces how a single missing enzyme can echo through the digestive process. As laboratory methods improved, researchers learned that enteropeptidase—an enzyme on the surface of the small intestine—acts like a starter switch for protein-digesting enzymes from the pancreas. Without that first spark, proteins are not properly broken down, and babies cannot absorb what they need, even with adequate calories.
In recent decades, awareness has grown as pediatric centers shared case series showing a recognizable pattern: early symptoms of congenital enteropathy due to enteropeptidase deficiency, including poor weight gain, diarrhea, and swelling from low blood protein. Some children were found to improve with tailored nutrition and enzyme support, which helped confirm the biology that clinicians suspected. Genetic testing then linked the condition to changes in the gene that tells the intestine how to make enteropeptidase, allowing families to receive clearer answers.
Over time, descriptions became more precise. What had once been grouped with general “failure to thrive” was separated from other rare digestive disorders based on the specific enzyme step that is missing. Not every early description was complete, yet together they built the foundation of today’s knowledge, including how to diagnose the deficiency earlier and how to support growth while avoiding complications.
Today, the history of congenital enteropathy due to enteropeptidase deficiency highlights steady progress: careful observation leading to biochemical insight, and then to genetic confirmation. Knowing the condition’s history helps explain why timely testing matters and why a baby who looks well at birth may need close follow-up once feeding begins. It also underscores a hopeful theme in rare diseases: when the missing piece is identified, care can be focused, families can plan, and outcomes often improve.